Dermatofibroma is a prevalent and benign tumor-like formation in the skin and is typically presented as a palpable nodule beneath the skin. Protheragen provides all-encompassing services in dermatofibroma healing which ranges from target identification to preclinical confirmation.
Overview of Dermatofibroma
Dermatofibroma, or benign fibrous histiocytoma, is a common benign skin lesion that appears as a small, hard, and hyperkeratotic nodule, mostly located on the extremities. Middle aged adults are more likely to be affected, with a slight female predominance. Diagnosis is often easy when the typical clinical and pathological features are present, but can be challenging because of some variant forms. These skin growths are often linked with prior mild local injuries like insect bites, and are best treated with surgical excision which is curative and has a low rate of recurrence.
Fig.1 A case study of pathological analysis of Granular Cell Dermatofibroma. (Cazzato G.,
et al., 2021)
Diagnostics Development for Dermatofibroma
Histopathological Analysis
Histopathological examination still remains central to the diagnosis of dermatofibroma. The classic presentation of dermatofibromas is a sharply circumscribed, non-encapsulated lesion in the dermis, often exhibiting a “storiform” arrangement of fibroblasts. Immunohistochemistry (IHC) plays an essential role in distinguishing dermatofibromas from clinically identical tumors such as dermatofibrosarcoma protuberans (DFSP) or even Kaposi sarcoma. Commonly used IHC markers include Factor XIIIa, CD34, and CD68, which illustrate the fibroblastic and histiocytic elements of the lesion. Granular cells, which are associated with some variants of dermatofibroma, can be detected using specific antibodies to lysosomal markers such as S-100 or CD68.
Molecular Diagnostics
Molecular diagnostics, including fluorescence in situ hybridization (FISH) and genetic sequencing, are being investigated to identify genetic changes linked to dermatofibromas. They can aid in the detection of particular changes in genes or chromosomes that could lead to the formation of atypical variants. As an illustration, certain gene changes are linked to dermatofibrosarcoma protuberans (DFSP) and can be utilized to differentiate benign dermatofibromas from the malignant ones. For instance, the PDGFRA and PDGFB gene fusions are associated with DFSP and can be detected by molecular diagnostics.
Therapeutics Development for Dermatofibroma
- Cryotherapy and Laser Therapy
Cryotherapy and laser therapy are two alternative methods used for the therapeutic of dermatofibromas, especially for those lesions that are hard to excise wholly. In cryotherapy, extreme cold is utilized to destroy the lesion, while for laser therapy, targeted light energy is utilized to ablate the affected tissue. Although these methods may not be as definitive as surgical excision, they tend to be helpful in reducing the size and appearance of the lesions.
- Topical Therapies
The application of imiquimod as a topical therapy has been studied for its potential use in the therapeutic of dermatofibromas. Imiquimod works as an immune response modifier and has been documented to cause regression of the lesion by bolstering the immune response. This technique is beneficial in cases where the patient is not a good surgical candidate.
Table 1. Therapeutics of Dermatofibroma.
| Therapeutics |
Mechanism |
Description |
Stage |
| Surgical Excision |
Physical removal |
Complete excision of the lesion with clear margins to prevent recurrence. |
Approved |
| Cryotherapy |
Thermal ablation |
Uses extreme cold to destroy the lesion, suitable for protruding lesions. |
Approved |
| Laser Therapy |
Photothermal effect |
Uses targeted light energy to remove the affected tissue. |
Approved |
| Topical Therapies (Imiquimod) |
Immune response modulation |
Stimulates the immune system to induce regression of the lesion. |
Approved |
| Immunotherapy |
Immune system enhancement |
Utilizes the body's immune system to target and destroy abnormal cells. |
Early Studies |
| Targeted Therapy |
Targeted molecular pathways |
Focuses on specific molecular targets involved in the pathogenesis of Dermatofibroma. |
Early Studies |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen offers comprehensive diagnostics and therapeutics development services for dermatofibroma. Our services encompass histopathological diagnosis, molecular and genetic diagnostics, and advanced imaging techniques. We also provide preclinical research services, including the development and testing of novel therapeutic approaches.
Disease Models
- Cell Line Models
- Skin Organoids
- Bleomycin-Induced Mouse Models
- Genetically Engineered Mouse Models
- Chemically Induced Guinea Pig Models
Protheragen's preclinical research services are designed to support the development of innovative diagnostics and therapeutics for dermatofibroma. Our team of experts utilizes state-of-the-art techniques and methodologies to conduct comprehensive preclinical studies. These services include the evaluation of new diagnostic markers, the development of novel therapeutic agents, and the assessment of drug efficacy and safety. If you are interested in our services, please feel free to contact us.
References
- Cazzato, Gerardo, et al. "Granular cell dermatofibroma: when morphology still matters." Dermatopathology 8.3 (2021): 371-375.
- Hardy, Céline SC, et al. "Immunohistochemical profiles of dermatofibroma and dermatofibrosarcoma protuberans: A scoping review." medRxiv (2024): 2024-10.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
